Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma

• Published in: Blood Vol. 106; no. 1; pp. 353 - 355
• Main Authors: Chang, Hong, Stewart, A. Keith, Qi, Xiao Ying, Li, Zhi Hua, Yi, Qi Long, Trudel, Suzanne
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 01.07.2005; The Americain Society of Hematology
• Subjects: Adult; Aged; Biological and medical sciences; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Hematologic and hematopoietic diseases; Humans; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunohistochemistry; Immunopathology; In Situ Hybridization, Fluorescence; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Multiple Myeloma - diagnosis; Multiple Myeloma - genetics; Predictive Value of Tests; Protein-Tyrosine Kinases - genetics; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor - genetics; Translocation, Genetic; Chromosomal aberration; Human; Immunohistochemistry; Immunopathology; Prognosis; Malignant hemopathy; Myeloma; Anatomic pathology; Immunoglobulinopathy; Abnormal chromosome B4; Lymphoproliferative syndrome; Fluorescence in situ hybridization; Abnormal chromosome D14; Abnormal chromosome; Genetics; Predictive factor; Chromosome translocation; Fibroblast growth factor receptor 3
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2005-01-0033

The t(4;14) translocation detected by fluorescence in situ hybridization (FISH) is an independent prognostic factor for an adverse outcome of multiple myeloma (MM). Because t(4;14) uniquely results in fibroblast growth factor receptor 3 (FGFR3) expression, decalcified, paraffin-embedded bone marrow biopsies were immunostained for FGFR3, and its expression was correlated with the t(4;14) status. FISH detected t(4;14) in 16 (19%) of 85 MM patient specimens, and immunocytochemistry detected aberrant FGFR3 expression in 13 (15%). Twelve (75%) t(4;14)-positive cases expressed FGFR3, and 12 (92%) FGFR3-positive cases harbored a t(4;14). FGFR3 expression and t(4;14) were strongly correlated (P < .001). FGFR3 expression by immunohistochemistry was associated with the immunoglobulin A (IgA) isotype (P < .001), a shorter progression-free survival (median, 11.5 versus 25.8 months; P < .001), and a shorter overall survival (median, 19.2 versus 46.3 months; P < .001).